Early findings from a small clinical trial provide evidence that a new cellular immunotherapy approach may be effective in treating metastatic solid tumors. In the trial, researchers from NCI genetically modified normal white blood cells, known as lymphocytes, from each patient to produce receptors that recognize and attack their specific cancer cells.
Lorlatinib (Lorbrena) is better than crizotinib (Xalkori) as an initial treatment for people with ALK-positive advanced non-small cell lung cancer, according to new clinical trial results. Treatment with lorlatinib also helped prevent new brain metastases.
For people with locally advanced esophageal cancer, a chemotherapy regimen called FLOT is the preferred treatment, according to results from a large clinical trial. People treated with FLOT lived much longer than those treated with another regimen.
Clinical Trials Information for Patients and Caregivers
Cancer screening studies test new ways of detecting cancer, such as blood tests, devices, and procedures. Participating in a cancer screening trial can help find new ways to detect cancer early when it may be more easily treated.
Cancer prevention studies test whether certain medicines or behaviors may reduce someone’s risk of cancer in the future. Learn more about cancer prevention studies, including what to expect and possible risks and benefits.
This phase 2/3 trial is screening for certain genetic changes in the tumors of people with non-small cell lung cancer that has spread or come back. People found to have specific gene changes are assigned to treatment trials testing targeted drugs.
This phase 1/2 clinical trial is testing combinations of two or three immunotherapy drugs and a vaccine for people with advanced endometrial cancer. In the first part of the trial, doctors will learn the best doses of the drugs and vaccine. The second part will assess how well the treatment combination works to prevent cancer from growing.
This phase 1 trial will test pomalidomide (Pomalyst) combined with the immunotherapy drug nivolumab (Opdivo) in people with cancers caused by viruses. Doctors will assess the safety and determine the best dose of the combination.
